Future studies should focus on combining tumor‐selective EV inhibitors, anti‐PD‐L1 nanobodies, and BATF inhibition—a strategy with strong preclinical rationale that may synergistically restore T cell function and counteract EV‐mediated immunosuppression, offering a clinically actionable approach to improve responses to immune checkpoint inhibitor therapy. Here, CD274 is linked to neoplasm.